Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy

摘要: Background Peripheral neuropathy is the dose-limiting toxicity of many oncology drugs, including paclitaxel. There large interindividual variability in neuropathy, and several risk factors have been proposed; however, not replicated. Here we present a comprehensive study aimed at identifying treatment physiopathology-related paclitaxel-induced cohort well-characterized patients. Patients methods Analyses included 503 patients with breast or ovarian cancer who received paclitaxel treatment. Paclitaxel dose modifications caused by were extracted from medical records self-reported symptoms collected. Multivariate logistic regression analyses performed to identify concomitant medications comorbidities associated neuropathy. Results Older had higher neuropathy: for each increase 1 year age, grade 3 increased 4% 5%, respectively. Cardiovascular drugs reductions (odds ratio [OR], 2.51; p = .006), stronger association beta-adrenergic antagonists. The total number also showed an (OR, 1.25; .012 drug increase). A modification predictive model that new identified gave area under curve 0.74 (p 1.07 × 10-10). Preexisting nerve compression syndromes seemed risk. Conclusion Baseline characteristics patients, age medications, could be used individuals high personalizing chemotherapy reducing severe Implications practice common adverse effect chemotherapeutics, targeted therapies, immune checkpoint inhibitors. About 40% survivors functional deficits this toxicity, some them irreversible. Currently, there are no effective treatments prevent treat This study, homogenously treated paclitaxel, comorbidities, demographic peripheral These serve whom alternative non-neurotoxic alternatives may considered.